Shares of Anavex Life Sciences Corp. ($AVXL) defied the broader market weakness and rallied on Thursday following a clinical trial readout. New York-based Anavex announced new data from the Phase 2b/3 study of its investigational drug candidate blarcamesin, administered as an once-daily oral formulation, demonstrating pre-specified clinical efficacy in people with early Alzheimer’s disease. The drug candidate, codenamed ANAVEX 2-73 worked through upstream activation of SIGMAR1, which is an integral membrane protein. Analysis of Phase 2b/3 data showed that over 48 weeks, blarcamesine significan…